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Abstract
Purpose.Doxorubicin (dox) still appears to be one of the most active drugs in the treatment of soft tissue sarcomas. However,
treatment duration is limited due to cumulative cardiotoxicity. A number of small studies from single institutions have
suggested activity of other analogues. In two studies the EORTC STBSG tested whether epirubicin (epi) is an alternative to
standard dose dox in the treatment of chemonaive patients with advanced soft tissue sarcoma.The present report gives the
® nal results of these studies.
Patients/Methods.In the ® rst study 210 patients were randomized to receive eitherdox or epi both at a dose of 75 mg/m
2given
as bolus injection at 3-week intervals. In the second study 334 patients were randomized to dox 75 mg/m
2, epi 150 mg/m
2
or epi 50 mg/m
2 days 1± 3, all given as bolus injection at 3-week intervals.
Results. In the ® rst study no differences in median survival and duration of response were found. Of 167 evaluable patients
the response rate was slightly in favour of dox (23% vs 18%) but at the expense of more toxicity.These data could suggest
that increasing the epi dose may lead to a greater antineoplastic effect with acceptable toxicity. In the second study 15% of
314 evaluable patients had an objective tumour response.There were no differences between the three groups with regard
to response rate, progression-free and overall survival, but both dose schedules of epi were more myelotoxic than dox.
Conclusion. Regardless of schedule and dose, epi is not superior to dox in the treatment of patients with advanced soft tissue
sarcomas. In addition, the results illustrate that the data from small studies of single institutions should always be confirmed
by large multi-institutional studies before being taken for granted.
Introduction
Chemotherapy has been extensively studied in soft
tissue sarcomas.
1,2 Unfortunately, their responsiveness
to chemotherapy has been disappointingly low. Doxo-
rubicinstillappearsto be oneof themostactive drugs.
1
Numerouspatients,bothnon-pretreatedandpretreated,
have received doxorubicin as a single agent with a
reported maximum response rate of about 25%.
1,3± 5
Presently,the EORTC SoftTissue and Bone Sarcoma
Group(STBSG) considerssingleagentdoxorubicinas
the standard treatment for advanced soft tissue
sarcomas. However, doxorubicin treatment is associ-
ated with cardiotoxicity, and unfortunately none of the
tested anthracycline analogs has shown superiority or
comparability to doxorubicin in terms of therapeutic
activity with less toxicity.
6± 8
In view of this, the EORTC STBSG has, in two
consecutive studies,tested whether epirubicin,which
is considered to be less cardiotoxic than doxoru-
bicin,
9could be an alternative to standard dose doxo-
rubicin in the treatment of chemonaive patients with
advanced soft tissue sarcoma. The data from these
studieshave beenpublishedpreviously,butthe present
report gives the overall and ® nal results of these stud-
ies
10,11 and summarizes the literature on epirubicin
in soft tissue sarcomas.
Patients and methods
Patients and methods have been described in detail
in previous publications
10,11 and will only be
summarized in the present paper. The studies were
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logically proven advanced soft tissue sarcomas.Other
eligibility criteria included: no history of signi® cant
cardiovascular disease, no prior malignant tumour,
no CNS metastases, presence of measurable lesions
not previously irradiated and adequate hepatic, renal
and bone marrow functions at entry. Informed
consent was obtained from all patients according to
local and/or national rules.
The studies aimed to compare time to progression,
duration of survival,responserate and responsedura-
tion, as well as acute and chronic toxicity. In the ® rst
study patients were randomized to receive an iv bolus
injection of either doxorubicinor epirubicinboth at a
dose of 75 mg/m
2 every 3 weeks, whereas in the
second the patients were randomized to receive an iv
bolus injection of doxorubicin 75 mg/m
2 or epiru-
bicin at a dose of either 150 mg/m
2 as a single iv
bolus injection or 3 iv bolus injections of 50 mg/m
2
on days 1± 3, all repeated every 3 weeks.The evalua-
tion of toxicity was done according to the recom-
mendation made by WHO for grading of acute and
subacute toxic effects, and in both studies doses were
modi® ed according to liver and bone marrow func-
tions.At least two cycles were given,and the maximal
accepted cumulative dose was 550 mg/m
2 for doxo-
rubicin and 1000 mg/m
2 for epirubicin. However, in
case of CR it was left to the discretion of the local
investigatorto continueto a highercumulativedosage.
Evaluation prior to treatment included history and
clinical examination, performance status, tumour
measurements,haematology,blood chemistries,plain
chest radiograph, ECG, appropriate scans and/or
radiographs for tumour measurements, and cardiac
ejectionfraction.Blood countswere performedweekly
during treatment for the initial two treatment cycles.
At follow-up clinical examination blood counts and
chemistries were performed before every cycle. All
baseline investigations were reported every second
course.
Patients were considered assessable for response if
they had received at least two cycles of chemotherapy.
Responsewas de® ned accordingto theWHO criteria.
All cases were reviewed by an externalreviewer.Exact
95% con® dence intervals for proportions were
calculated for response rates. Duration of response,
progression-free and overall survival were estimated
by use of the Kaplan± Meyer method.
12The log-rank
test was used for comparison between survival
curves.
13 Calculation of study power was done
according to standards of the EORTC STBSG.
11
Results
Patient characteristics
In both studies the covariates age, sex, performance
status, histological grades, sites of involvement, and
prior treatment were evenly distributed among the
treatment groups. Patient characteristics are given in
Table 1. In the ® rst study 210 patients were entered
by 18 institutions. A total of 28 patients were
considered ineligible due to inadequate histology
(n=16), previous chemotherapy (n=3), insufficient
performance status (n=2), non-measurable lesions
(n=4) and others (n=3). Of the 182 eligible patients,
15 were not evaluable (Table 1). In the second study
a total of 334 patients from 34 centers were included.
Fifteen patients were considered as ineligible for the
trial for the following reasons: inadequate histology
(n=8), no target lesion (n=1), concurrent disease
(n=2), age >70 years (n=1), performance status >2
(n=1), prior breast cancer (n=1) and prior
chemotherapy (n=1). An additional 5 patients were
lost during follow-up. In total 20 patients were
excluded from the analysis, which consequently was
based on 314 patients (Table 1).
A central histopathology review was performed in
89% and 83% of the patients, respectively. Leiomy-
osarcomas contributed 32% and 40% whereas
malignant ® brous histiocytoma contributed 21% and
10%, respectively. The histopathological types were
equally distributedamong the treatment groups(data
not shown).Prior radiotherapy was given to 31% and
22% of the patients, respectively.
Treatment compliance
In neither of the studies did the treatment compli-
ance differ among the treatment groups. In the ® rst
study the patients received a median of 5 cycles
(1± 23), and the median total dose in the 2 groups
was 338 mg/m
2 (75± 916) of doxorubicin and 363
mg/m
2of epirubicin,respectively.In the secondstudy
the patients received a median of 4 cycles (0± 11),
and the median total dose and the relative dose
intensity as computed according to the Hryniuk
method
13 were for doxorubicin299 mg/m
2 (50± 599)
and 97%, for 1-day epirubicin 592 mg/m
2 (131±
1343) and 94%, and for 3-day epirubicin 481 mg/m
2
(50± 1105) and 92%, respectively.
Toxicity
When given in equimolar doses doxorubicin caused
more haematological toxicity (Table 2) and alopecia
Table 1. Patients’ Characteristics
Characteristics Study No. 1 Study No. 2
Registered patients 210 334
Ineligible patients 28 15
Insufficient data 15 5
Included patients 167 314
Median age, years 54 (18± 80) 52 (19± 70)
Male/females 87/80 154/160
Histological grade
1 22 (21%) 65 (21%)
2 38 (37%) 124 (39%)
3 44 (42%) 125 (40%)
32 O. S.Nielsen et al.as compared with epirubicin, whereas there was no
differencebetween the other toxicitiesregistered(data
not shown).Increasingthe dose of epirubicinresulted
in more severe toxicity with both the 1-day and the
3-day regimenas compared with doxorubicinin terms
of haematological toxicity (Table 2) and rate of infec-
tion.Apart from these toxicities very few grade 3 and
grade 4 toxicities were observed, and no signi® cant
differences were observed between the other toxici-
ties (data not shown). In the 3-day epirubicin group
three toxic deaths were reported:two patients died of
neutropenic infection and one due to cardiotoxicity.
One patient died of cardiotoxicity after 8 cycles of
doxorubicin.
Response
The progression-free survival was similar with the
three treatment schedules studied (Fig. 1). Neither
did the overall survival differ between the treatment
schedules (Fig. 2).The survival curve characteristics
are given inTable 3.
The response data are shown in Table 4. The
`progression’ category includes early progressions as
well as early deaths due to malignant disease. In the
® rst study the overall response rate was 25% in the
group receiving doxorubicin and 18% in the group
treated with epirubicin, but the difference was not
Table 2. Worst WHO grades 3+4 haematological toxicities across all cycles in the different treat-
ment regimens (% of patients)
*
Treatment Leucopenia (%) Neutropenia (%) Thrombocytopenia (%)
Dox 75 mg/m
2 29 43 4
Epi 75 mg/m
2 4 3 0
Dox 75 mg/m
2 38 51 2
Epi 150 mg/m
2 63 73 14
Epi 33 50 mg/m
2 75 77 18
*See original publications for a detailed description of toxicities.
10,11
Figure 1. Actuarial estimate of progression-free survival of
patients with soft tissue sarcoma treated with A:Doxorubicin 75
mg/m
2day 1 or epirubicin 75 mg/m
2day 1,and B:Doxorubicin
75 mg/m
2 day 1, epirubicin 150 mg/m
2 day 1 or epirubicin 50
mg/m
2 days 1, 2 and 3 every 3 weeks.
Figure 2. Actuarial estimate of overall survival of patients
with soft tissue sarcoma treated with A: Doxorubicin 75 mg/m
2
day 1 or epirubicin 75 mg/m
2 day 1, and B: Doxorubicin 75
mg/m
2
day 1, epirubicin 150 mg/m
2 day 1 or epirubicin 50
mg/m
2 days 1, 2 and 3 every 3 weeks.
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response rates among the three groups of the second
study. The overall response rates were 14% in the
doxorubicin group, 15% in the 1-day epirubicin
group, and 14% in the 3-day epirubicin group.The
data in Table 4 may suggest that the response rates
are lower in the second study as compared with those
of the ® rst study.
Discussion
The presentstudies on advanced soft tissue sarcomas
showed that equimolar doses of doxorubicin and
epirubicin produced response rates favouring doxo-
rubicin (although not statistically signi® cant) but at
the cost of moretoxicity.Despite a signi® cantincrease
of both haematological and non-haematologicalacute
side-effects, none of the two tested high-dose epiru-
bicin schedules demonstrated any superior outcome
compared with standard dose doxorubicin.Similarly,
both the progression-free and overall survival were
similar to those obtained in other trials performed by
the EORTC STBSG in comparable patients.
However, the response rates obtained in the second
of the presentedstudieswere disappointingand lower
than that of the ® rst study (Table 4). A similar trend
of decreasing response rates has been found in other
studies.
1,7,9,11,15A differencein doseintensitybetween
the two studies was not the reason for the poor
responserate.Neither was there a differencein patient
selection (prognosticfactors)between the two groups.
In the second study the number of leiomyosarcomas
was slightly higher than that of the ® rst studyÐ a
difference that may partly explain the lower response
rates. Both studies were also subject to the same
responsereview system,making it unlikelythat differ-
ences in responses reported offers an explanation.
We are presently analysing possible explanations for
these low responserates.On the other hand,although
the responserates were lower in the second study,the
progression rates remained the same (Table 3).
Treatment duration with doxorubicin is limited
because of cardiotoxicity associated with cumulative
dose. It is therefore important to test anthracycline
analogs with potentially less toxicity and equal or
better activity. However, at present only few analogs
have been evaluated and primarily in small studies
from single institutions with limited number of
patients.
6± 8,16± 18Some of these studies indicated that
epirubicin may be active in soft tissue sarcomas,
whereas carminomycin,mitoxantroneas well as other
analogs were shown to be inactive.Some studies have
indicated that epirubicin may be very active as a part
of combination chemotherapy regimens but whether
it’s a better alternative than doxorubicinhas not been
demonstratedin these studies.
20,21The presentresults
on epirubicin may illustrate that the data from such
small studies of single institutions should always be
con® rmed by large multi-institutional studies before
being taken for granted.Pegylated liposomal doxoru-
bicin (caelyx) representsa novel formulation to deliver
doxorubicin,which may increase tumour effect with
less toxicity. In a phase 2 second line study caelyx did
not show activity in soft tissue sarcomas.
19 In the
EORTC STBSG we recently completed a rand-
omized phase 2 study investigating caelyx and doxo-
rubicin given as ® rst line treatment in soft tissue
sarcomas, but at present data analysis is still ongo-
ing.
22 Finally, the possibility of ameliorating anthra-
cycline cardiotoxicity by use of compounds like
dexrazoxane is presently under investigation.
23
In conclusion, regardless of schedule and dose
epirubicin is not superior to doxorubicinin the treat-
ment of patients with advanced soft tissue sarcomas.
Table 3. Progression-free survival (PFS) and overall survival (OS) characteristics
*
Treatment 1-year PFS (%) Median PFS (weeks) 1-year OS (%) Median OS (weeks)
Dox 75 mg/m
2 11 16 41 41
Epi 75 mg/m
2 14 12 41 48
Dox 75 mg/m
2 13 17 45 45
Epi 150 mg/m
2 15 16 43 48
Epi 33 50 mg/m
2 18 14 45 45
*See original publications for a detailed description of toxicities.
10,11
Table 4. Response to treatment
*
Treatment CR (%) PR (%) NC (%) PD (5) NE (%)
Dox 75 mg/m
2 7 18 45 30 Ð
Epi 75 mg/m
2 5 13 40 42 Ð
Dox 75 mg/m
2 2 12 50 36 Ð
Epi 150 mg/m
2 3 12 43 41 Ð
Epi 33 50 mg/m
2 3 11 39 43 5
*CR, complete response; PR, partial response; NC, no change; PD, progressive disease; NE, not
evaluable.
See original publications for a detailed description of toxicities.
10,11
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